Resveratrol inhibits growth of orthotopic pancreatic tumors through activation of FOXO transcription factors

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Roy, Sanjit K ^a   Chen, Qinghe ^a,b   Fu, Junsheng ^a   Shankar, Sharmila ^a   Srivastava, Rakesh K ^a  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^b VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CASPASE 3; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DNA; LUCIFERASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RESVERATROL; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; CELL CYCLE PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL NUCLEUS; CELL VIABILITY; CLONOGENIC ASSAY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; ENZYME ACTIVATION; ENZYME ASSAY; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; FOXO GENE; GEL MOBILITY SHIFT ASSAY; GENE; GENE DELETION; GENE EXPRESSION; GENE INDUCTION; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NICK END LABELING; NONHUMAN; PANCREAS CANCER; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING; CELL CYCLE; CELL SURVIVAL; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; PANCREAS TUMOR; TUMOR CELL LINE;

AGOUTI PACA; MUS;

APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; STILBENES;

EID: 80053199541     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025166     Document Type: Article

References (44)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Hruban RH, (2001) Pancreatic cancer: from genes to patient care. J Gastrointest Surg 5: 583-587.
3. Li D, (2001) Molecular epidemiology of pancreatic cancer. Cancer J 7: 259-265.
4. Gold EB, Goldin SB, (1998) Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin N Am 7: 67-91.
5. Jaffee EM, Hruban RH, Canto M, Kern SE, (2002) Focus on pancreas cancer. Cancer Cell 2: 25-28.
6. McKenna S, Eatock M, (2003) The medical management of pancreatic cancer: a review. Oncologist 8: 149-160.
7. Shankar S, Singh G, Srivastava RK, (2007) Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci 12: 4839-4854.
8. Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, et al. (2010) Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer 127: 257-268.
9. Shankar S, Nall D, Tang SN, Meeker D, Passarini J, et al. (2011) Resveratrol inhibits pancreatic cancer stem cell characteristics in human and kras transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One 6: e16530.
10. Anderson MJ, Viars CS, Czekay S, Cavenee WK, Arden KC, (1998) Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. Genomics 47: 187-199.
11. Van Der Heide LP, Hoekman MF, Smidt MP, (2004) The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 380: 297-309.
12. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, et al. (2000) Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 20: 8969-8982.
13. Dijkers PF, Birkenkamp KU, Lam EW, Thomas NS, Lammers JW, et al. (2002) FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol 156: 531-542.
14. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ, (2003) Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 89: 2110-2115.
15. Bokoch GM, Der CJ, (1993) Emerging concepts in the Ras superfamily of GTP-binding proteins. Faseb J 7: 750-759.
16. Shih C, Weinberg RA, (1982) Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 29: 161-169.
17. Marshall MS, (1995) Ras target proteins in eukaryotic cells. FASEB J 9: 1311-1318.
18. Schaeffer HJ, Weber MJ, (1999) Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 19: 2435-2444.
19. Han J, Ulevitch RJ, (1999) Emerging targets for anti-inflammatory therapy. Nat Cell Biol 1: E39-40.
20. Davis RJ, (2000) Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
21. Robinson MJ, Cobb MH, (1997) Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9: 180-186.
22. Kyriakis JM, Avruch J, (1996) Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem 271: 24313-24316.
23. Lubinus M, Meier KE, Smith EA, Gause KC, LeRoy EC, et al. (1994) Independent effects of platelet-derived growth factor isoforms on mitogen-activated protein kinase activation and mitogenesis in human dermal fibroblasts. J Biol Chem 269: 9822-9825.
24. Shankar S, Chen Q, Srivastava RK, (2008) Inhibition of PI3K/AKT and MEK/ERK pathways act synergistically to enhance antiangiogenic effects of EGCG through activation of FOXO transcription factor. J Mol Signal 3: 7.
25. Davis R, Singh KP, Kurzrock R, Shankar S, (2009) Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. Oncol Rep 22: 1473-1478.
26. Srivastava RK, (2000) Intracellular mechanisms of TRAIL and its role in cancer therapy. Mol Cell Biol Res Commun 4: 67-75.
27. Cappellini A, Tabellini G, Zweyer M, Bortul R, Tazzari PL, et al. (2003) The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression. Leukemia 17: 2157-2167.
28. Chen Q, Ganapathy S, Singh KP, Shankar S, Srivastava RK, (2010) Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One 5: e15288.
29. Datta SR, Brunet A, Greenberg ME, (1999) Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927.
30. Hutzen B, Willis W, Jones S, Cen L, Deangelis S, et al. (2009) Dietary agent, benzyl isothiocyanate inhibits signal transducer and activator of transcription 3 phosphorylation and collaborates with sulforaphane in the growth suppression of PANC-1 cancer cells. Cancer Cell Int 9: 24.
31. Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, et al. (2008) Sulforaphane targets pancreatic tumor-initiating cells by NF-{kappa}B-induced anti-apoptotic signaling. Gut.
32. Shankar S, Ganapathy S, Srivastava RK, (2007) Green tea polyphenols: biology and therapeutic implications in cancer. Front Biosci 12: 4881-4899.
33. Armour SM, Baur JA, Hsieh SN, Land-Bracha A, Thomas SM, et al. (2009) Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy. Aging (Albany NY) 1: 515-528.
34. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, et al. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
35. Tang TT, Dowbenko D, Jackson A, Toney L, Lewin DA, et al. (2002) The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor. J Biol Chem 277: 14255-14265.
36. Shankar S, Ganapathy S, Hingorani SR, Srivastava RK, (2008) EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci 13: 440-452.
37. Srivastava RK, Unterman TG, Shankar S, (2010) FOXO transcription factors and VEGF neutralizing antibody enhance antiangiogenic effects of resveratrol. Mol Cell Biochem 337: 201-212.
38. Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, et al. (2006) Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108: 4178-4186.
39. Daitoku H, Fukamizu A, (2007) FOXO transcription factors in the regulatory networks of longevity. J Biochem 141: 769-774.
40. Imai S, Armstrong CM, Kaeberlein M, Guarente L, (2000) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403: 795-800.
41. de Boer VC, de Goffau MC, Arts IC, Hollman PC, Keijer J, (2006) SIRT1 stimulation by polyphenols is affected by their stability and metabolism. Mech Ageing Dev 127: 618-627.
42. Shankar S, Ganapathy S, Srivastava RK, (2008) Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis and angiogenesis. Clinical Cancer Res 14: 1-16.
43. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, et al. (2001) Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20: 6073-6083.
44. Furuyama T, Kitayama K, Shimoda Y, Ogawa M, Sone K, et al. (2004) Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J Biol Chem 279: 34741-34749.